SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

Posted a reply to that seeking alpha fake

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Bescaredxx Member Profile
 
Followed By 2
Posts 121
Boards Moderated 0
Alias Born 11/21/16
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/11/2017 8:01:50 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:09:06 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:08:13 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:07:22 PM
Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development "NetworkNewsWire" - 9/28/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/28/2017 7:02:33 AM
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile... "GlobeNewswire Inc." - 9/28/2017 6:30:00 AM
Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development "NetworkNewsWire" - 9/26/2017 8:45:00 AM
Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects "NetworkNewsWire" - 9/19/2017 8:45:00 AM
Biosynthesis Technology Could Transform Cannabinoid Production "NetworkNewsWire" - 9/13/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 5:02:12 PM
Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences "GlobeNewswire Inc." - 9/6/2017 7:30:00 AM
MJAC 2017 Speaker Update - How venture capital and cryptocurrency are converging as the future of cannabis investing "InvestorsHub NewsWire" - 8/30/2017 10:29:33 PM
PotNetwork Holdings, Inc Confirmed for MJAC 2017 "InvestorsHub NewsWire" - 8/28/2017 10:43:55 AM
MJAC 2017 International Cannabis Conference - Discount Code "InvestorsHub NewsWire" - 8/25/2017 6:50:56 PM
Book your ticket now for InvestorsHubs International Cannabis Conference "InvestorsHub NewsWire" - 8/23/2017 12:50:25 PM
MJAC 2017 - Speaker Update - Investing In The U.S. Cannabis Market "InvestorsHub NewsWire" - 8/22/2017 1:27:13 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/14/2017 7:03:20 AM
Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthri... "GlobeNewswire Inc." - 8/14/2017 6:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/7/2017 7:01:10 AM
Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal ... "GlobeNewswire Inc." - 8/7/2017 6:45:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/1/2017 4:19:17 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/1/2017 7:31:42 AM
Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights "GlobeNewswire Inc." - 8/1/2017 7:30:00 AM
Bescaredxx   Thursday, 10/05/17 09:31:55 PM
Re: None
Post # of 965 
Posted a reply to that seeking alpha fake news today! They would not publish it so here it is!

Ok so before you post any article you might want to do a little bit more DD. Try contacting the company see what has progressed.

Lets start with this, 5 phase 3 trials. Well each one has about 33% chance of being FDA approved. So that means at least one or even two make it.

1) Do they have the cash to get there? Well yes they do!

2) Do they have good management with FDA experience? Yes they do!

3) Do they have a broad pipeline meeting all time frames so far? Yes they do.

4) Is it possible to do a placebo trial on patients unaware they are even receiving treatment? Well thats pretty pointless. (FXS)

5) Do you know how much the phase 3 trials for FXS cost? Ok ill tell you about 5-10 million total. Best and cheapest runway for success!

6) How about there are no known treatments for spectrum disorders.

7) How about patented past 2030 with orphan drug designation giving almost a decade of exclusive marketing!

Ok now lets talk about O/A or osteoarthritis.

Met the most important secondary endpoints! Worked in men and not women. Restructure this with the FDA for phase 3 probably gonna have a solid update for this in December.

O/A largest market but also costly phase3 ($20+ million 300+ patients)

How about Zyn001? Well the only pro THC derived transdermal synthetic thats patent protected with all the same as above minus the results.

I tell you what my bet is here! any placebo test is an open and shut case

i believe that passing on this opportunity to buy the stock will be a large mistake people will look back and say wow i could have bought that for how much?! Its already traded at $25 before any results, has a low float enough cash till 2019 and is in the largest market space with the highest potential growth in the next 5 years!

Sorry for the rant here but i have alot to say and this article was pitiful! Longs will be winners here mark my words!

Thanks for the support of all my friends who held on through this rough ride, we should be rewarded handsomely!

-HT


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist